2021 was a landmark year for private capital fundraising across many sectors with the excitable market allowing for plentiful, early exits. The biopharma industry saw particular interest as the COVID-19 pandemic drew attention to potential gains to be made from the sector. Has the appetite for investing in drug development waivered now the pandemic has subsided?
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?